Showing results (21-30 of 202) with videos related to
Sort By:
Pageof 21
Chemmedchem|October 27, 2016
Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy?Brian Budke, Wei Lv, Alan P Kozikowski, et al.Journal of Medicinal Chemistry|December 14, 2004
Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3Nicola Micale, Rajendran Vairagoundar, Alexander G Yakovlev, et al.Molecular Pharmacology|January 27, 2004
Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor populationAttila Tóth, Peter M Blumberg, Zili Chen, et al.ACS Medicinal Chemistry Letters|May 4, 2013
From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational DesignLi-Fang Yu, Han-Kun Zhang, Hendra Gunosewoyo, et al.Nature Reviews. Drug Discovery|December 13, 2005
NAAG peptidase inhibitors and their potential for diagnosis and therapyJia Zhou, Joseph H Neale, Martin G Pomper, et al.Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Synthesis and pharmacological characterization of bivalent ligands of epibatidine at neuronal nicotinic acetylcholine receptorsZhi-Liang Wei, Yingxian Xiao, Kenneth J Kellar, et al.Journal of Medicinal Chemistry|November 13, 2004
Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridizationJia Zhou, Rong He, Kenneth M Johnson, et al.Journal of Medicinal Chemistry|April 7, 2016
Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51Wei Lv, Brian Budke, Michal Pawlowski, et al.Chemmedchem|August 8, 2006
Synthesis and pharmacological evaluation of 8- and 9-substituted benzolactam-v8 derivatives as potent ligands for protein kinase C, a therapeutic target for Alzheimer's diseaseUlrich R Mach, Nancy E Lewin, Peter M Blumberg, et al.Bioorganic & Medicinal Chemistry|March 17, 2004
2,3-disubstituted 6-azabicyclo[3.2.1]octanes as novel dopamine transporter inhibitorsJosefina Quirante, Xavier Vila, Josep Bonjoch, et al.Pageof 21